Alpha RegistryClaim a profile
Published mark

Nautilus Biotechnology, Inc.

NASDAQ: NAUT. Canonical company identity and public leadership record.

US

Record source reportedRecord not claimedNo Eval published
Follow companySave PDF
Alpha ID
alpha:company:0e1028ca-1667-45de-91f2-95823f879caf
SEC CIK
0001808805
Record version
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 16, 2026
Newest evidence
Apr 28, 2026
Monitoring
Not yet monitored Details
Integrity
Not yet signed Methodology
CEO
Sujal PatelSince Apr 28, 2026
Chair
Not published
Independent
6 / 88 directors published
Published claims
313 distinct sources
Evidence records
90 pinned
Source conflicts
0None open

Built from 3 distinct sources and 9 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.

CorroboratedSource reportedAlpha inferenceNot disclosed

Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works

CFO CHANGED

Anna Mowry executive of Nautilus Biotechnology, Inc., effective 2026-04-28.

EffectiveEffective Apr 28, 2026E3

Monitoring

Continuous

What the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.

  • Identityunclaimed
    Published
  • Evidencesource_reported
    Published
  • Evaluationnot_evaluated
    Published
  • MonitoringNot yet published for this record.
    Not published
  • AuthorityNot yet published for this record.
    Not published
  • Freshnesscurrent
    Published

Leadership

Evidence
RolePersonSinceStatusClaim
Chief Financial Officer and TreasurerAnna MowryApr 2026currentSource reportedE3
Chief People OfficerGwen WeldApr 2026currentSource reportedE4
Chief Marketing OfficerKentaro SuzukiApr 2026currentSource reportedE5
General CounselMatthew MurphyApr 2026currentSource reportedE6
Senior Vice President, Product DevelopmentSubra SankarApr 2026currentSource reportedE7
Chief Executive Officer, President, Secretary and DirectorSujal PatelApr 2026currentSource reportedE8

Board of directors

Evidence

8 directors published. 6 of 8 with a published determination are independent.

DirectorStatusSinceCommitteesClaim
Farzad NazemIndependent2021CompensationSource reportedE2
Karen AkinsanyaIndependent2022None publishedSource reportedE2
Matthew McIlwainIndependent2021AuditAudit; Nominating and Governance · ChairNominating and Governance, chairSource reportedE2
Melissa EpperlyIndependent2021Audit, chairAudit · Chair; Nominating and GovernanceNominating and GovernanceSource reportedE2
Michael AltmanIndependent2021CompensationSource reportedE2
Parag MallickNot independent2021None publishedSource reportedE2
Sujal PatelNot independent2021None publishedSource reportedE2
Vijay PandeIndependent2021Nominating and GovernanceSource reportedE2
Karen AkinsanyaIndependence not publishedNot publishedCompensationSource reportedE9
Matthew L. PosardIndependence not publishedNot publishedAuditCompensation, chairSource reportedE9

Committees and risk ownership

Evidence
CommitteeChairMembersRisks assigned
AuditMelissa EpperlyMelissa Epperly, Matthew L. Posard, Matthew McIlwainNot described in the published record
Audit · Chair; Nominating and GovernanceNot publishedMelissa EpperlyNot described in the published record
Audit; Nominating and Governance · ChairNot publishedMatthew McIlwainNot described in the published record
CompensationMatthew L. PosardMatthew L. Posard, Farzad Nazem, Karen Akinsanya, Michael AltmanNot described in the published record
Nominating and GovernanceMatthew McIlwainMatthew McIlwain, Melissa Epperly, Vijay PandeNot described in the published record
Committee AppointmentMelissa Epperly: chair, Audit
Source reportedE9
company:0e1028ca-1667-45de-91f2-95823f879caf:committee_appointment:20
Committee AppointmentMatthew L. Posard: member, Audit
Source reportedE9
company:0e1028ca-1667-45de-91f2-95823f879caf:committee_appointment:21
Committee AppointmentMatthew McIlwain: member, Audit
Source reportedE9
company:0e1028ca-1667-45de-91f2-95823f879caf:committee_appointment:22
Committee AppointmentMatthew L. Posard: chair, Compensation
Source reportedE9
company:0e1028ca-1667-45de-91f2-95823f879caf:committee_appointment:24
Committee AppointmentFarzad Nazem: member, Compensation
Source reportedE9
company:0e1028ca-1667-45de-91f2-95823f879caf:committee_appointment:25
Committee AppointmentKaren Akinsanya: member, Compensation
Source reportedE9
company:0e1028ca-1667-45de-91f2-95823f879caf:committee_appointment:26
Committee AppointmentMichael Altman: member, Compensation
Source reportedE9
company:0e1028ca-1667-45de-91f2-95823f879caf:committee_appointment:27
Committee RecordNominating and Governance: Chair Matthew McIlwain; Members Matthew McIlwain (Chair); Melissa Epperly; Vijay Pande
Source reportedE9
company:0e1028ca-1667-45de-91f2-95823f879caf:committee_record:28
Committee AppointmentMatthew McIlwain: chair, Nominating and Governance
Source reportedE9
company:0e1028ca-1667-45de-91f2-95823f879caf:committee_appointment:29
Committee AppointmentMelissa Epperly: member, Nominating and Governance
Source reportedE9
company:0e1028ca-1667-45de-91f2-95823f879caf:committee_appointment:30
Committee AppointmentVijay Pande: member, Nominating and Governance
Source reportedE9
company:0e1028ca-1667-45de-91f2-95823f879caf:committee_appointment:31

Control and voting power

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Authority to act

Evidence and agent registry

Who can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.

Principal executive officerSujal Patel, Chief Executive Officer, President, Secretary and Director, from Apr 28, 2026
Source reportedE8
company:0e1028ca-1667-45de-91f2-95823f879caf:leadership_role:18
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
bind
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
agents
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
delegations

Financials and market context

Evidence
Security ListingNAUT (NASDAQ)
Source reportedE1
company:0e1028ca-1667-45de-91f2-95823f879caf:security_listing:32
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 17, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.

Governance and policies

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Risk, audit, and cyber

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

AI oversight and accountability

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Compensation

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Other published claims

Evidence

Published Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.

Legal NameNautilus Biotechnology, Inc.
Source reportedE1
company:0e1028ca-1667-45de-91f2-95823f879caf:legal_name:1
Entity StatusPublic listing published
Source reportedE1
company:0e1028ca-1667-45de-91f2-95823f879caf:entity_status:3

Not yet in this record

Coverage

A gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.

  • Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
  • OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
  • FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
  • CompensationNot reviewed. Pay design shows how incentives are governed.
  • GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
  • Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
  • AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
  • LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
  • RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
  • CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
  • AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
  • Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
  • Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
  • Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
  • Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
  • Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
  • This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.

Subject and corrections

Public-role doctrine

This record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.

Basis
Published company record built from public sources
Sources
9 evidence records cited. 0 with redistribution rights.
Never published
Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
Record claimed
No
Open disputes
0
Identity ownership
unclaimed
Claiming not yet available

If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.

Evidence

Authority and rights
  1. E1
    Alpha canonical company public projection
    Alpha canonical company public projection. canonical identity. Retrieved Oct 16, 2026. Cited by 4 Claims.
    Open web
    Rights not recorded, link only
    Evidence not pinned
  2. E2
    Nautilus Biotechnology, Inc. DEF 14A 2025-04-29
    sec proxy. Published Apr 29, 2025. Retrieved Apr 28, 2026. Cited by 8 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  3. E3
    NAUT DEF 14A executive officers
    sec filing. Published Apr 28, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  4. E4
    NAUT DEF 14A executive officers
    sec filing. Published Apr 28, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  5. E5
    NAUT DEF 14A executive officers
    sec filing. Published Apr 28, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  6. E6
    NAUT DEF 14A executive officers
    sec filing. Published Apr 28, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  7. E7
    NAUT DEF 14A executive officers
    sec filing. Published Apr 28, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  8. E8
    NAUT DEF 14A executive officers
    sec filing. Published Apr 28, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  9. E9
    Audit
    board_seats. board seats. Cited by 13 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned

What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 16, 2026
  • Anna Mowry executive of Nautilus Biotechnology, Inc., effective 2026-04-28.
  • Gwen Weld executive of Nautilus Biotechnology, Inc., effective 2026-04-28.
  • Kentaro Suzuki executive of Nautilus Biotechnology, Inc., effective 2026-04-28.
  • Matthew Murphy executive of Nautilus Biotechnology, Inc., effective 2026-04-28.
  • Subra Sankar executive of Nautilus Biotechnology, Inc., effective 2026-04-28.
  • Sujal Patel executive of Nautilus Biotechnology, Inc., effective 2026-04-28.
  • Karen Akinsanya seat on Nautilus Biotechnology, Inc., effective 2022-01-01.
  • Farzad Nazem seat on Nautilus Biotechnology, Inc., effective 2021-01-01.
  • Matthew McIlwain seat on Nautilus Biotechnology, Inc., effective 2021-01-01.
  • Melissa Epperly seat on Nautilus Biotechnology, Inc., effective 2021-01-01.
  • Michael Altman seat on Nautilus Biotechnology, Inc., effective 2021-01-01.
  • Parag Mallick seat on Nautilus Biotechnology, Inc., effective 2021-01-01.
  • Sujal Patel seat on Nautilus Biotechnology, Inc., effective 2021-01-01.
  • Vijay Pande seat on Nautilus Biotechnology, Inc., effective 2021-01-01.
  • Audit · Chair; Nominating and Governance committee of Nautilus Biotechnology, Inc., effective 2021-01-01.
  • Melissa Epperly member of Audit · Chair; Nominating and Governance, effective 2021-01-01.
  • Audit; Nominating and Governance · Chair committee of Nautilus Biotechnology, Inc., effective 2021-01-01.
  • Matthew McIlwain member of Audit; Nominating and Governance · Chair, effective 2021-01-01.
  • Farzad Nazem member of Compensation, effective 2021-01-01.
Appearance

Alpha Governance PBC. The Registry records reported facts and Alpha's assessments separately. A missing fact is not evidence that it is false.

Record alpha:company:0e1028ca-1667-45de-91f2-95823f879caf, version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce. https://registry.alpha.ac/companies/nautilus-biotechnology-inc

Navigate

On this record

  1. Overview
  2. Monitoring4
  3. Leadership6
  4. Board10
  5. Committees5
  6. Control and voting0
  7. Authority to act4
  8. Financials1
  9. Governance0
  10. Risk0
  11. AI oversight0
  12. Legal0
  13. Compensation0
  14. Other published claims3
  15. Coverage gaps17
  16. Linked people15
  17. Subject and corrections6
  18. Evidence9
  19. Version historyvpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

Linked records

Registry

Appearance

esc
  • Actions
    Switch to agent viewJSON, Markdown, MCP
  • Copy Alpha IDalpha:company:0e1028ca-1667-45de-91f2-95823f879caf
  • Cite this recordNautilus Biotechnology, Inc.
  • Copy canonical URLregistry.alpha.ac/companies/nautilus-biotechnology-inc
  • Copy as MarkdownWith assertion states
  • Report an error
  • Theme: System
  • Theme: Light
  • Theme: Dark
  • Records
    Nautilus Biotechnology, Inc.Company
  • Anna MowryPerson
  • Gwen WeldPerson
  • Kentaro SuzukiPerson
  • Matthew MurphyPerson
  • Subra SankarPerson
  • Sujal PatelPerson
  • Farzad NazemPerson
  • Karen AkinsanyaPerson
  • Matthew McIlwainPerson
  • Melissa EpperlyPerson
  • Michael AltmanPerson
  • Parag MallickPerson
  • Vijay PandePerson
  • Karen AkinsanyaPerson
  • Matthew L. PosardPerson
  • Sections
    OverviewNautilus Biotechnology, Inc.
  • MonitoringNautilus Biotechnology, Inc.
  • LeadershipNautilus Biotechnology, Inc.
  • BoardNautilus Biotechnology, Inc.
  • CommitteesNautilus Biotechnology, Inc.
  • Control and votingNautilus Biotechnology, Inc.
  • Authority to actNautilus Biotechnology, Inc.
  • FinancialsNautilus Biotechnology, Inc.
  • GovernanceNautilus Biotechnology, Inc.
  • RiskNautilus Biotechnology, Inc.
  • AI oversightNautilus Biotechnology, Inc.
  • LegalNautilus Biotechnology, Inc.
  • CompensationNautilus Biotechnology, Inc.
  • Other published claimsNautilus Biotechnology, Inc.
  • Coverage gapsNautilus Biotechnology, Inc.
↑ ↓ move↵ openThis record only

Report an error

Reports attach to the Claim and go to an Alpha analyst through the correction form. Corrections are versioned, and the original stays in history.